Clinical Progress of CAR-T Cell Therapy for Hematologic Malignancies

ZHAO Liping¹, PAN Jing², FENG Xiaoming¹*

(¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; ² Boren Clinical Translational Center, Department of Hematology, Beijing Boren Hospital, Beijing 100070, China)

Abstract:

As a new type of cellular therapy, CAR-T (chimeric antigen receptor T cell), which is engineered to express a chimeric receptor to recognize the tumor antigen, can specifically eliminate tumor cells. CAR-T has attracted much attention due to its promising value in the treatment of a variety of hematological malignancies. However, more and more clinical studies have shown that CAR-T can cause a series of adverse events, affecting the prognoses of patients. This review aims to summarize the evolution of CAR construct design, the applications of CAR-T in acute lymphoblastic leukemia, acute myeloid leukemia, lymphoma and multiple myeloma and the related adverse events, and provide the discussion on how to improve the efficacy and safety of CAR-T therapy.

CSTR: 32200.14.cjcb.2022.01.0026